Understanding SARS-CoV-2-Mediated Inflammatory Responses: From
Por um escritor misterioso
Descrição
Currently there is no effective antiviral therapy for SARS-CoV-2 infection, which frequently leads to fatal inflammatory responses and acute lung injury. Here, we discuss the various mechanisms of SARS-CoV-mediated inflammation. We also assume that SARS-CoV-2 likely shares similar inflammatory responses. Potential therapeutic tools to reduce SARS-CoV-2-induced inflammatory responses include various methods to block FcR activation. In the absence of a proven clinical FcR blocker, the use of intravenous immunoglobulin to block FcR activation may be a viable option for the urgent treatment of pulmonary inflammation to prevent severe lung injury. Such treatment may also be combined with systemic anti-inflammatory drugs or corticosteroids. However, these strategies, as proposed here, remain to be clinically tested for effectiveness.
Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research - The Lancet Respiratory Medicine
Associations between Children's Exposure to PM2.5 and their Serum Inflammatory Responses in Taiwan - Aerosol and Air Quality Research
SARS‐CoV‐2 Alpha, Beta, and Delta variants display enhanced Spike‐mediated syncytia formation
New research supports finding explaining why some patients may test positive for COVID-19 long after recovery
COVID-19: inflammatory responses, structure-based drug design and potential therapeutics
Study confirms SARS-CoV-2 spike glycoprotein promotes a hyper-inflammatory immune response
Understanding the pivotal roles of ACE2 in SARS-CoV-2 infection: from structure/function to therapeutic implication, Egyptian Journal of Medical Human Genetics
Small NIH study reveals how immune response triggered by COVID-19 may damage the brain
Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities
Toll-Like Receptor 4-Dependent Platelet-Related Thrombosis in SARS-CoV-2 Infection
Eje Renina Angiotensina, Enzima Convertidora de Angiotensina 2 y Coronavirus
SARS-CoV-2 and innate immunity: the good, the bad, and the “goldilocks”
COVID-19 infection: an overview on cytokine storm and related interventions, Virology Journal
